Literature DB >> 30286252

Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.

Minsun Jung1, Bohyun Kim1, Kyung Chul Moon1,2.   

Abstract

AIMS: Immunohistochemical (IHC) staining for cytokeratin (CK) 5/6, CD44 and CK20 has been significantly associated with the prognosis of urinary bladder urothelial carcinoma, and probably reflects its molecular characteristics. We aimed to investigate the IHC-based subgroups and their prognostic effects on non-muscle-invasive papillary upper tract urothelial carcinoma (UTUC). METHODS AND
RESULTS: IHC staining for CK5/6, CK20 and CD44 was analysed in 211 patients with non-muscle-invasive papillary UTUC. Staining was classified as showing a negative, positive or normal pattern. We found that CK5/6-negative, CD44-negative and CK20-positive tumours were distinctly high-risk subgroups that were associated with high grade (CK5/6-negative, P < 0.001; CD44-negative, P < 0.001; CK20-positive, P = 0.017) and frequent intravesical recurrence (CK5/6-negative, P = 0.002). Using survival analysis with Kaplan-Meier and log-rank tests, we found that these IHC subgroups were correlated with poor progression-free (CK5/6-negative, P = 0.001; CD44-negative, P = 0.009; CK20-positive, P = 0.031) and cancer-specific (CK5/6-negative, P = 0.009) survival. Furthermore, CK5/6 negativity was an independent prognostic factor for shorter progression-free (P = 0.009) and cancer-specific (P = 0.045) survival. CK5/6 improved Harrell's C-indices for progression-free (0.68-0.77, P = 0.029) and cancer-specific (0.59-0.77, P < 0.001) survival. When markers were combined, luminal-like subtypes showed poor prognoses.
CONCLUSIONS: We demonstrated that IHC staining for CK5/6, CD44 and CK20 was significantly associated with the clinicopathological characteristics and prognoses of patients with non-muscle-invasive papillary UTUC. The IHC subgroups may be correlated with the molecular characteristics of non-muscle-invasive papillary UTUC.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD44; carcinoma; cytokeratin 20; cytokeratin 5/6; immunohistochemistry; papillary; prognosis; transitional cell; upper tract urothelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30286252     DOI: 10.1111/his.13763

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

1.  Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.

Authors:  Minsun Jung; Jeong Hoon Lee; Bohyun Kim; Jeong Hwan Park; Kyung Chul Moon
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

2.  Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.

Authors:  Tician Schnitzler; Nadina Ortiz-Brüchle; Ursula Schneider; Isabella Lurje; Karolina Guricova; Alexander Buchner; Gerald Bastian Schulz; Axel Heidenreich; Nadine Therese Gaisa; Ruth Knüchel; Stefan Garczyk
Journal:  Cell Oncol (Dordr)       Date:  2020-05-22       Impact factor: 6.730

Review 3.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

4.  Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Authors:  Cosima Völkel; Noémi De Wispelaere; Sören Weidemann; Natalia Gorbokon; Maximilian Lennartz; Andreas M Luebke; Claudia Hube-Magg; Martina Kluth; Christoph Fraune; Katharina Möller; Christian Bernreuther; Patrick Lebok; Till S Clauditz; Frank Jacobsen; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer H Krech; David Dum; Till Krech; Andreas H Marx; Ronald Simon; Eike Burandt; Anne Menz
Journal:  Virchows Arch       Date:  2021-09-24       Impact factor: 4.064

Review 5.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Matteo Landriscina; Vincenza Conteduca; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

Review 6.  Non-muscle invasive bladder cancer biomarkers beyond morphology.

Authors:  Camilla De Carlo; Marina Valeri; Devin Nicole Corbitt; Miriam Cieri; Piergiuseppe Colombo
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

Review 7.  Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer.

Authors:  Amira Abugomaa; Mohamed Elbadawy; Hideyuki Yamawaki; Tatsuya Usui; Kazuaki Sasaki
Journal:  Cells       Date:  2020-01-17       Impact factor: 6.600

8.  Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression.

Authors:  Minsun Jung; Insoon Jang; Kwangsoo Kim; Kyung Chul Moon
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

9.  Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.

Authors:  Stefan Garczyk; Felix Bischoff; Ursula Schneider; Reinhard Golz; Friedrich-Carl von Rundstedt; Ruth Knüchel; Stephan Degener
Journal:  Virchows Arch       Date:  2021-03-01       Impact factor: 4.064

10.  Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.

Authors:  Tim Muilwijk; Murat Akand; Frank Van der Aa; Vincent De Coninck; Marc Claessens; Robert Hente; Markus Eckstein; Yves Allory; Louis Libbrecht; Steven Joniau; Thomas Gevaert
Journal:  J Cell Mol Med       Date:  2021-06-29       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.